Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIN457 extension study in Behçet's posterior or panuveitis
2009-013901-33Phase 3Terminated
- Sponsor
- Novartis
- Start
- Oct 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in posterior uveitis, Behçet's disease-associated panuveitis and Hyalitis (3 arms), sponsored by Novartis. Primary endpoints: Rate of recurrent ocular exacerbations, Long-term safety over 1 year and 1 more. Started Oct 2009; status: terminated.
02
Drugs
secukinumab
03
Conditions
posterior uveitisBehçet's disease-associated panuveitisHyalitis
Beyond the preview
Go deeper on 2009-013901-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013901-33.